To test the feasibility of "bedside" closed-loop control we will use an approach comprised of standard sensor-augmented pump therapy during the day using off-the-shelf devices and overnight closed-loop control using experimental devices in supervised outpatient setting. We hypothesize that the AAA control system will prevent nocturnal hypoglycemia and will increase time within target (80-140 mg/dl) overnight for 5 consecutive nights compared to 5 consecutive nights with CGM-augmented pump alone. Additionally we have an exploratory hypothesis that overnight control will lead to improved time in target during the day.